Skip to main content
SpringerLink
Log in

Positron emission tomography in the management of lymphomas: a summary

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jack AS. The classification of lymphomas: a new beginning or the end of an era? Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1155-8.

  2. Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of Non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1157-6.

  3. Kogel KE, Sweetenham JW. Current therapies in Hodgkin's disease. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1156-7.

  4. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1154-9.

  5. Evin-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1164-7.

  6. Schiepers C, Filmont J-E, Czernin J. PET for staging Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1165-6.

  7. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1159-4.

  8. Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1162-9.

  9. Reske S. PET and restaging including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1167-4.

  10. Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron Emission Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1166-5.

  11. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1169-2.

  12. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16:260–267.

    Google Scholar 

  13. Visvikis D, Ell PJ. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives. Eur J Nucl Med Mol Imaging 2003; DOI 10.1007/s00259-003-1168-3.

  14. Zheng J, Tan T. The application of radionuclide antisense therapy for malignant tumours. Nucl Med Commun 2001; 22:469–472.

    Google Scholar 

  15. Urbain JL. Sense, antisense and common sense. J Nucl Med 2001; 42:1670–1672.

    Google Scholar 

  16. Pan D, Ghambir SS, Toyokuni T, et al. Rapid synthesis of a 5'-fluorinated oligodeoxy-nucleotide: a model antisense probe for use in imaging with positron emission tomography (PET). Bioorg Med Chem Lett 1998; 8:1317–1320.

    Google Scholar 

  17. Liang Q, Nguyen K, Satyamurthy N, Barrio JR, Phelps ME, Gambhir SS, Herschman HR. Monitoring adenoviral DNA delivery, using a mutant herpes simplex virus type 1 thymidine kinase gene as a PET reporter gene. Gene Ther 2002; 9:1659–1666.

    Google Scholar 

  18. Liang Q, Gotts J, Satyamurthy N, et al. Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther 2002; 6:73–82.

    Google Scholar 

  19. Haberkorn U, Altmann A. Imaging methods in gene therapy of cancer. Curr Gene Ther 2001; 1:163–182.

    Google Scholar 

  20. Antoch G, Freudenberg LS, Stattaus J, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR 2002; 179:1555–1560.

    Google Scholar 

  21. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43:1339–1342.

    Google Scholar 

  22. Nakamoto Y, Osman M, Cohade C, et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med 2002; 43:1137–1143.

    Google Scholar 

  23. Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von Schulthess GK. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 2002; 29:922–927.

    Google Scholar 

  24. O'Doherty MJ, McDonald E, Barrington SF, Mikhaeel NG, Schey S. PET in the management of lymphoma. Clin Oncol 2002; 14:415–426.

    Google Scholar 

  25. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; DOI 10.1182.

Download references

Author information

Authors and Affiliations

  1. Clinical PET Centre, Guy's and St Thomas NHS Trust, St Thomas Hospital, Lambeth Palace Road, London, SE1 7EH, UK

    M. J. O'Doherty

  2. Mount Vernon Cancer Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK

    P. J. Hoskin

Authors
  1. M. J. O'Doherty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. J. Hoskin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. J. O'Doherty.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Doherty, M.J., Hoskin, P.J. Positron emission tomography in the management of lymphomas: a summary. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S128–S130 (2003). https://doi.org/10.1007/s00259-003-1170-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1170-9

Keywords

Search

Navigation